Samyang Biopharm, the Samyang Group's biopharmaceutical affiliate, announced on June 4 that it signed a contract with Seattle-based Compliment Corporation to introduce a technology for facilitating tumor penetration.
The technology in question is a biomaterial named Opus, which plays a role in disconnecting a protein that connects cancer cells. The U.S. start-up has an exclusive license worldwide.
Through this contract, the Korean company has acquired an exclusive sub-license to manufacture and sell anti-cancer drugs using its own drug delivery technology and products that combine Compliment's biotechnology.
“We anticipate that if Opus successfully disconnects hard substances between cancer cells and induces an anti-cancer drug to cancer tissues, the anti-cancer drug will be able to penetrate the inside of cancer tissues and thus maximize the effects of anti-cancer treatments,” said Samyang Biopharm in a statement.
There has been a certain limit to existing drugs, since they cannot penetrate the inside of cancer tissues, and it takes longer to treat cancer as a result. Hence, the development of a new anti-cancer drug with this biomaterial is expected to effectively shorten the length of treatment for cancer.
An official at Samyang Biopharm remarked, "Our company will spur the development of a new anti-cancer drug that can treat resistant or incurable cancer by integrating the soon-to-be introduced material into our anti-cancer drug using drug delivery technology."